{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:01:39Z","timestamp":1784718099244,"version":"3.55.0"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Depression and anxiety are highly prevalent among individuals with opioid use disorder (OUD), and antidepressants are frequently prescribed in conjunction with medication for opioid use disorder. However, the relationship between specific antidepressants and continued illicit opioid use during buprenorphine-based treatment remains insufficiently characterized. This exploratory analysis aimed to investigate the association between prescribed antidepressants and illicit opioid use among adults with OUD receiving buprenorphine\/naloxone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This sub-analysis included 92 participants from a randomized controlled trial of 141 adults with OUD treated with buprenorphine\/naloxone over 16\u2009weeks in an outpatient setting. Participants were eligible if they received at least one antidepressant for a minimum duration of 10\u2009days. Depressive and anxiety symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7), respectively. The primary outcome was the proportion of urine drug screens positive for illicit opioids. Point-biserial correlation analyses were conducted to examine associations between individual antidepressants and illicit opioid use. Antidepressants demonstrating significant associations were subsequently included in multivariable linear regression models adjusted for age, treatment allocation group, and buprenorphine elimination rate constant. Interaction effects were also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean (SD) PHQ-9 score was 10.0 (5.4), and the median (IQR) GAD-7 score was 5.5 (2.0-13.75). Escitalopram 10\u2009mg was the only antidepressant significantly associated with illicit opioid use, demonstrating a negative correlation (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sub>pb<\/jats:sub>\n                      \u2009=\u2009\u2212.28). Multivariable regression analyses indicated that escitalopram exposure and older age were independently associated with a lower proportion of opioid-positive urine tests. A statistically significant interaction between escitalopram exposure and age was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Exposure to escitalopram 10\u2009mg was associated with reduced illicit opioid use among individuals receiving buprenorphine\/naloxone, with the magnitude of this association modified by age. Further large-scale prospective studies are warranted to confirm these findings and to elucidate the underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342261456634","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:01:47Z","timestamp":1783594907000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation of Illicit Opioid Use With Antidepressants in Adults Receiving Buprenorphine\/Naloxone: An Exploratory Analysis"],"prefix":"10.1177","author":[{"given":"Hesham Farouk","family":"Elarabi","sequence":"first","affiliation":[{"name":"Delmon Consultancy and Health Planning, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marsden","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology and Neuroscience-King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdu","family":"Adem","sequence":"additional","affiliation":[{"name":"Khalifa University for Science and Technology, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"Al Ghafri","sequence":"additional","affiliation":[{"name":"Delmon Consultancy and Health Planning, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-6268","authenticated-orcid":false,"given":"Ahmad","family":"Muneer","sequence":"additional","affiliation":[{"name":"Maudsley Health, Al Amal Psychiatry Hospital\u2013Emirates Health Services, Dubai, UAE"},{"name":"Centre for Drug Research, University Sains Malaysia, George Town, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Sciences\u2013University of Aberdeen, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Assaf","sequence":"additional","affiliation":[{"name":"Fakih Medical Center, Abu Dhabi, UAE"},{"name":"Okasha Institute of Psychiatry, Neuropsychiatric Department, Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.15m09963"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2018.1510148"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109551"},{"key":"e_1_3_3_6_2","unstructured":"National Institutes on Drug Abuse (US). (2020 April 1). Common Comorbidities with Substance Use Disorders Research Report. NCBI Bookshelf. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK571451\/"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.35946\/arcr.v40.1.07"},{"key":"e_1_3_3_8_2","unstructured":"Substance Abuse and Mental Health Services Administration. Substance use disorder treatment for people with co-occurring disorders. In Treatment Improvement Protocol (Report TIP 42). 2020. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep20-02-01-004.pdf"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2021.101978"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnac029"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2020.1726549"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15394"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd008373.pub2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.37897\/rjpp.2022.2.2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.014"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14001"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2491063"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2019.1662150"},{"issue":"12","key":"e_1_3_3_20_2","first-page":"972","article-title":"Validation of the Tunisian version of the Patient Health Questionnaire-9 (PHQ-9) for depression screening","volume":"98","author":"Jomli R","year":"2020","unstructured":"Jomli R, Belhaj H, Ouali U, Zgueb Y, Jemli H, Nacef F. Validation of the Tunisian version of the Patient Health Questionnaire-9 (PHQ-9) for depression screening. Tunis Med. 2020;98(12):972-979.","journal-title":"Tunis Med"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-017-0155-1"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2021.1979349"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871527321666220301122807"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.009"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.03.042"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117392"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104800"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43821"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.18f122"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.007"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2011.596982"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550490590949569"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261456634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342261456634","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261456634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:10:38Z","timestamp":1784715038000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342261456634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":32,"alternative-id":["10.1177\/29767342261456634"],"URL":"https:\/\/doi.org\/10.1177\/29767342261456634","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"29767342261456634"}}